Curated News
By: NewsRamp Editorial Staff
May 15, 2026

NanoViricides Advances NV-387 Toward Phase II for MPox

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • NanoViricides advances NV-387 toward Phase II for MPox in DRC, gaining regulatory edge in broad-spectrum antiviral market.
  • NV-387, a nanoviricide candidate, targets MPox via orphan-drug strategy with FDA designation for measles and applications for MPox/smallpox.
  • NanoViricides' broad-spectrum antiviral NV-387 aims to treat MPox, measles, and smallpox, improving global health outcomes.
  • NanoViricides' NV-387 uses nanomaterial technology to fight multiple viruses including RSV, COVID, and influenza simultaneously.

Impact - Why it Matters

This news matters because it highlights progress in developing broad-spectrum antiviral treatments that could address multiple viral diseases, including MPox and measles. If successful, NV-387 could provide a much-needed therapy for populations in regions like the Democratic Republic of Congo, where MPox is endemic, and for other viral outbreaks. The orphan drug designation for measles also underscores the potential to treat a neglected disease that still causes significant morbidity worldwide. For investors, the company's regulatory advancements signal potential growth and validation of its nanomedicine platform.

Summary

NanoViricides, Inc. (NYSE American: NNVC) has announced the filing of its quarterly report for the period ended March 31, 2026, showcasing significant progress in its antiviral drug development pipeline. The company is advancing its broad-spectrum antiviral candidate NV-387 toward Phase II clinical development for MPox in the Democratic Republic of Congo, where regulatory approval for the trial has already been obtained. Additionally, NanoViricides is pursuing an orphan-first regulatory strategy, having secured FDA orphan drug designation for measles after the quarter, with additional applications targeting MPox and smallpox. This strategy aims to expedite the development and approval process for these critical antiviral therapies.

NanoViricides is a clinical-stage company specializing in creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is designed to treat a range of viral infections, including RSV, COVID, Long COVID, Influenza, MPox, smallpox, and measles. The company also has other advanced candidates, such as NV-HHV-1 for shingles. The company's technology is based on proprietary nanoviricide technology licensed from TheraCour Pharma, Inc., and it holds exclusive licenses for several antiviral drugs. The company emphasizes that while it is making strides, the path to drug development is lengthy and requires substantial capital, with no assurance of success at this stage.

The press release also highlights the company's broader pipeline, which includes drugs for HIV, hepatitis, herpes, influenza, and emerging viruses like Ebola. The focus is on leveraging its nanomedicine platform to create targeted therapies. For investors, the latest news and updates are available in the company’s newsroom at https://ibn.fm/NNVC. The full press release can be accessed at https://ibn.fm/osO0q. This announcement underscores NanoViricides' commitment to addressing unmet medical needs in antiviral treatments, particularly for orphan diseases and emerging viral threats.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Advances NV-387 Toward Phase II for MPox

blockchain registration record for this content.